RecruitingPHASE1, PHASE2NCT05480449

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stephan Grupp MD PhD
Principal Investigator
Allison Barz Leahy, MD
Children's Hospital of Philadelphia
Intervention
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)(biological)
Enrollment
89 target
Eligibility
0-29 years · All sexes
Timeline
2022 – 2029

Study locations (1)

Collaborators

Children's Hospital of Philadelphia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05480449 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials